US Senate Removes Hemp-Restricting Language: A Win for the Industry

The US hemp industry has been on a regulatory tightrope since the 2018 Farm Bill, with stakeholders watching closely for federal actions impacting the future of hemp production, cannabinoids, and consumer access. In a pivotal move in July 2025, the US Senate removed language that would have significantly restricted hemp products, marking the most consequential US hemp legislation update in recent years. This decision preserves hemp's legality, supports industry growth, and maintains opportunities for regulatory clarity and innovation.

Below, we examine the Senate’s action, its implications for cannabis compliance, and what’s next for hemp businesses, investors, and consumers.

Background: The 2025 Federal Hemp Ban Proposal

Earlier this year, federal lawmakers introduced provisions in the Senate’s draft Agriculture Appropriations Bill that would have prohibited the production, sale, and distribution of hemp-derived products containing any cannabinoids other than CBD or CBG. This legislative push responded to concerns over intoxicating cannabinoids like delta-8 and delta-10 THC, many of which are synthesized from hemp extracts rather than naturally occurring in the plant.

The hemp industry braced for sweeping consequences:

• Potential ban of most hemp-derived THC products (including popular delta-8 and delta-10 items)
• Threats to multi-billion-dollar supply chains and small hemp businesses
• Confusion and uncertainty for retailers and consumers

For context, see Cannabis Business Times: Effort to Ban Intoxicating Hemp Fails in U.S. Senate

Senate Removes Hemp-Restricting Language

On July 29, 2025, the US Senate eliminated the hemp-restricting commercial language from its bill. Key highlights from this US hemp legislation update:

• The controversial ban wording was dropped after strong pushback from industry and advocacy groups and a public threat by Sen. Rand Paul (R-KY) to stall the legislation (source).
• Lawmakers emphasized the economic and innovation risks of a complete ban, stressing the need for regulation over prohibition.
• As of September 2025, there is no federal ban on hemp-derived cannabinoids outside of traditional marijuana restrictions.

What Remains in Effect? Current US Hemp Regulatory Environment

While federal prohibition was averted, the Senate’s bill does not resolve all regulatory issues. The 2018 Farm Bill’s definition of hemp remains, allowing for up to 0.3% delta-9 THC by dry weight. Most compliance requirements established since then are still active, including:

Licensing and Production

• Hemp producers must register with the USDA or applicable state programs.
• All hemp (including for cannabinoids) must be tested to confirm delta-9 THC content is below federal thresholds.
• Learn more about licensing on the USDA Hemp Program site

Cannabinoid Products Compliance

• Businesses are subject to state-level regulations on product formulation, testing, labeling, and sales.
• The legality of products like delta-8, delta-10, and THC-O varies by state—some ban specific cannabinoids, while others regulate them as hemp.
• Packaging and labeling must not make therapeutic claims without FDA approval.
• Products must generally be sold in child-resistant, tamper-evident packaging as dictated by state law or the FDA.

Social Equity and Licensing

• Many states dedicate a portion of hemp or cannabis licenses to social equity applicants affected by past cannabis enforcement. For instance, states like Washington and Massachusetts have active social equity programs (see examples from Business Law Today).
• The federal government does not yet provide a social equity mandate for hemp licensing but continues to monitor equity impacts.
• Some states (e.g., New York, Massachusetts) reserve new retail licenses for applicants from communities disproportionately impacted by prior cannabis laws (source).

State vs. Federal: Patchwork Remains

Despite this national win, state-level hemp laws vary widely and remain in force. Some states have:

• Banned or tightly regulated intoxicating hemp-derived cannabinoids, regardless of federal legality (e.g., California, Texas)
• Imposed stricter product testing or packaging mandates

For example, Texas Senate recently proposed legislation that would criminalize production, sale, or possession of any hemp product containing cannabinoids other than CBD or CBG (Texas Policy Research Center). Enforcement dates and details are in flux state by state, with growing divergence between federal rules and local enforcement.

What’s Next? Congressional and Regulatory Outlook

While the Senate’s action is a clear industry victory, hemp legislation remains a battleground:

• The House of Representatives continues to propose stricter restrictions. Until both chambers agree, wholesale federal reform is on hold (Fox Business).
• The next Farm Bill revision is likely in 2026, leaving the industry in a state of careful monitoring and advocacy.
• Ongoing pressure from agencies—including the FDA—may still prompt rulemaking around cannabinoids, packaging, and labeling (Congressional Research Service).

Key Takeaways for Businesses: Compliance and Risk Management

Stay Vigilant on State and Federal Changes

• While federal prohibition was averted, state enforcement varies. Always check state and local laws before developing or selling hemp-derived products, especially cannabinoids beyond CBD.
• Regularly update compliance protocols for testing, labeling, and recordkeeping. Many states require batch-level lab results and child-proof packaging.
• Watch for federal Food and Drug Administration (FDA) or USDA actions on product standards or interstate sales.

Licensing Considerations

• Producers and processors must be licensed through the USDA or relevant state agency. Renewal and reporting schedules vary (often annual).
• Social equity licensing incentives may apply at the state level but not federally for hemp as of September 2025.
• Consider additional certifications (GMP, ISO) for downstream customers—many major distributors require these for supply-chain integrity.

Product Development and Marketing

• Brands should anticipate continued scrutiny over claims and cannabinoid content. Do not make health claims without clinical evidence and, ideally, FDA review.
• Prepare for possible changes in product packaging, warning requirements, or sales bans on cannabinoids at either state or federal levels.

Takeaways for Consumers

• Hemp-derived products (including non-intoxicating cannabinoids) remain federally legal if containing <0.3% delta-9 THC.
• State rules may be stricter—always check local laws, especially for products like delta-8 or vapes.
• New state bans may phase in suddenly—watch for compliance notices from reputable dispensaries and online retailers.

Enforcement Updates and Penalties

• Federal enforcement on hemp-derived cannabinoids remains light as long as products meet the 2018 Farm Bill definition. However, the FDA and local agencies continue to monitor for mislabeling, adulteration, and unsubstantiated claims.
• State enforcement varies: In Texas, for example, failure to liquidate prohibited inventory before state deadlines could result in Class A misdemeanors with fines and potential jail time (source).
• Retailers are strongly advised to maintain compliance documentation and stay up-to-date on both federal and state changes.

Conclusion: Policy Watch and Industry Advocacy Are Vital

The Senate’s removal of restrictive hemp language in 2025 is a crucial win, but hemp businesses must remain adaptable as patchwork state rules and potential federal changes continue. Both established operators and newcomers should prioritize strong compliance systems, stay tuned to legislative activity, and consider participation in industry advocacy groups.

For ongoing insights and personalized compliance support, visit CannabisRegulations.ai as your trusted resource for US hemp regulation, licensing, and cannabis compliance updates.